The ANO6 Knockout A-549 Polyclonal Cells consist of a CRISPR/Cas9-edited population of A-549 cells with disrupted ANO6 gene expression. This polyclonal pool comprises a heterogeneous mixture of cells carrying various loss-of-function modifications introduced by CRISPR/Cas9-mediated gene targeting. The knockout model abolishes the calcium-activated phospholipid scramblase and chloride channel functions encoded by ANO6, enabling robust functional studies without the confounding effects of clone-specific artifacts. The polyclonal format provides a biologically relevant system that minimizes clonal variation typically observed in monoclonal derivatives, making it suitable for a range of assays examining phosphatidylserine signaling, coagulation, and ion transport.
A-549 cells, originally isolated from a human lung adenocarcinoma of a 58-year-old Caucasian male, serve as a well-established model of alveolar type II epithelium. These adherent epithelial cells are a cornerstone in lung cancer research, retaining key characteristics such as surfactant production and responsiveness to external stimuli. Their epithelial origin makes them particularly useful for studying cell polarity, junctional complexes, and epithelial-mesenchymal transition, processes that intersect with ANO6-mediated phospholipid scrambling and cytoskeletal reorganization.
ANO6 encodes a dual-function protein acting as a calcium-activated phospholipid scramblase and a chloride channel. Upon intracellular calcium elevation, often mediated by STIM1/Orai1 store-operated calcium entry or GPCR agonists such as thrombin, ANO6 catalyzes the bidirectional translocation of phosphatidylserine from the inner to the outer plasma membrane leaflet. This externalization event is critical for the assembly of the prothrombinase complex, where coagulation factors Factor Xa and Factor Va bind to exposed phosphatidylserine to generate thrombin. ANO6 also interacts with the actin cytoskeleton via ERM proteins (ezrin, radixin, moesin) and with calcium-calmodulin and PLSCR1, linking scramblase activity to cytoskeletal dynamics and cell volume regulation. Downstream, ANO6-driven phosphatidylserine exposure serves as an ‘eat-me’ signal for apoptotic cell clearance, while its chloride channel function contributes to ion homeostasis.
Disruption of ANO6 in the A-549 lung adenocarcinoma background provides a physiologically relevant context for dissecting the role of scramblase activity in epithelial-derived tumor cells. ANO6 expression has been implicated in cancer cell migration, invasion, and apoptosis resistance; therefore, this knockout model allows investigation of how loss of phosphatidylserine externalization affects tumor cell behavior. Additionally, as A-549 cells recapitulate aspects of alveolar epithelium, the system can be used to study ANO6’s contribution to coagulation at the lung epithelial surface, with relevance to acute lung injury and pulmonary thrombosis. The model also enables exploration of chloride current-mediated epithelial ion transport and cell volume regulation in a cancer setting.
This ANO6 knockout polyclonal cell population supports a broad spectrum of functional investigations. Researchers can employ flow cytometry-based Annexin V binding or lactadherin staining to quantify phosphatidylserine exposure in response to calcium elevation. Calcium imaging with Fluo-4 or Fura-2 can be combined with scramblase activity measurements to delineate signaling kinetics. Thrombin generation assays assess thrombogenic potential, while apoptosis studies utilize caspase-3/7 activation and TUNEL staining to evaluate efferocytosis. Migration and invasion assays in Boyden chambers permit analysis of ANO6’s role in tumor cell motility. Standard techniques such as Western blotting, RT-qPCR, and co-immunoprecipitation with ERM proteins or actin facilitate interrogation of the ANO6 interactome. Patch clamp electrophysiology provides direct readout of chloride channel function. The product thus supports drug screening for scramblase modulators and studies on viral entry mechanisms, including Ebola virus exploitation of phosphatidylserine receptors. For additional technical details, please contact Ascent Research.
